<DOC>
	<DOCNO>NCT00080938</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs temozolomide may make tumor cell sensitive radiation therapy . Combining temozolomide radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give temozolomide together whole-brain radiation therapy work treat patient brain metastasis secondary non-small cell lung cancer .</brief_summary>
	<brief_title>Temozolomide Radiation Therapy Treating Patients With Brain Metastasis Secondary Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine intracranial response rate patient brain metastasis secondary non-small cell lung cancer treat whole brain radiotherapy temozolomide . Secondary - Determine time radiological progression patient treat regimen . - Determine time neurological progression ( confirm magnetic resonance imaging ( MRI ) ) patient treat regimen . - Determine overall survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients undergo whole brain radiotherapy daily , 5 day week , 2 week ( 10 fraction ) . Patients also receive concurrent oral temozolomide daily day 1-14 . Beginning 3 week completion chemoradiotherapy , patient receive oral temozolomide daily day 1-5 . Treatment repeat every 28 day 6 course absence neurologic ( Central Nervous System , CNS ) progression unacceptable toxicity . Patients follow every 3 month 2 year . ACCRUAL : A total 26 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer ( NSCLC ) , include follow histology : Squamous cell carcinoma Adenocarcinoma Large cell carcinoma Bronchoalveolar carcinoma All variant NSCLC At least 1 bidimensionally measurable brain metastasis Confirmed MRI within past two week , compute tomography ( CT ) scan acceptable Biopsy require Not eligible surgical resection radiosurgery brain metastasis Systemic disease immediate need chemotherapy Age &gt; =18 year ECOG Performance status 01 More 12 week life expectancy Adequate hematologic , renal , liver function demonstrate laboratory value perform within two week , inclusive , prior administration study drug registration Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Bilirubin ≤ 2 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤ 2 time upper limit normal ( 5 time ULN liver metastasis present ) Alkaline phosphatase ≤ 2 time ULN ( 5 time ULN liver metastasis present ) Creatinine ≤ 1.6 mg/dL Fertile patient must use effective contraception Prior biologic therapy allow More 4 week since prior chemotherapy Prior radiotherapy local control palliative therapy painful bony lesion allow Prior surgery brain metastasis allow At least 4 week since prior radiotherapy ≥ 15 % bone marrow ( 2 week &lt; 15 % bone marrow ) recover No prior radiotherapy ≥ 50 % bone marrow Concurrent radiotherapy painful bony lesion allow provided 15 % bone marrow irradiate HIV positive AIDSrelated illness Poor medical risk due active nonmalignant systemic disease Frequent vomit There medical condition would interfere oral medication intake ( e.g. , partial bowel obstruction ) Pregnant nursing Prior temozolomide Prior radiotherapy brain , include stereotactic radiosurgery different lesion Concurrent intensity modulate radiotherapy 3D cranial radiotherapy Other concurrent investigational agent Other concurrent treatment brain metastasis Other concurrent chemotherapy study radiotherapy Concurrent growth factor induce elevation blood count purpose administration study drug schedule dose interval allow treatment study drug high dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>tumor metastatic brain</keyword>
</DOC>